Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...8283848586878889909192...123124»
  • ||||||||||  Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion. (Pubmed Central) -  Jun 3, 2021   
    Now, treatment options have expanded to include immunotherapy, as exemplified by the immune checkpoint inhibitor (ICI) atezolizumab combined with the antiangiogenic agent bevacizumab...Cost containment and treatment sequencing may be facilitated by characterisation of predictive positive and negative biomarkers. With these considerations in mind, this review and expert opinion focused on advanced HCC in the Asia-Pacific region offers perspectives of multiple stakeholders, including physicians, payer systems, and patients.
  • ||||||||||  Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal:  Mitochondrial Dynamics and Liver Cancer. (Pubmed Central) -  Jun 3, 2021   
    In addition, some data are accumulating on the role played by mitochondrial dynamics during cancer development, and specifically on how such dynamics act directly on tumor cells or indirectly on cells responsible for tumor aggression and defense. Here, we review the data that suggest mitochondrial dynamics to be involved in the development of liver tumors.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma (clinicaltrials.gov) -  Jun 2, 2021   
    P2,  N=33, Active, not recruiting, 
    Here, we review the data that suggest mitochondrial dynamics to be involved in the development of liver tumors. Trial completion date: May 2021 --> May 2022 | Trial primary completion date: May 2021 --> May 2022
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma (clinicaltrials.gov) -  Jun 2, 2021   
    P=N/A,  N=240, Active, not recruiting, 
    Trial completion date: May 2021 --> May 2022 | Trial primary completion date: May 2021 --> May 2022 Recruiting --> Active, not recruiting | N=482 --> 240 | Trial completion date: Dec 2024 --> Jun 2023 | Trial primary completion date: Dec 2021 --> Jun 2022
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Review, Journal, Checkpoint inhibition, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker:  Immune checkpoint inhibitors in endometrial cancer. (Pubmed Central) -  Jun 2, 2021   
    It appears clear that immune check-point inhibitors will have a definite place in the management of EC, both as single agent or in combination with other targeted agents. In this review, we summarize the current evidence of immune check point blockade and the identification of potential biomarkers, beyond MSI-H or MMRd, that could help to predict response to this agents in correlation with the genomic EC subtypes.
  • ||||||||||  lenvatinib / Generic mfg.
    [VIRTUAL] Pembrolizumab/quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress () -  Jun 1, 2021 - Abstract #ESMOGI2021ESMO_GI_288;    
    P2
    Additionally, lenvatinib, an inhibitor of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor alpha, KIT, and RET, is a first-line treatment option in advanced HCC and has shown promising antitumor activity in combination with pembrolizumab in an early-stage study. MK-1308A-004 (NCT04740307) is an open-label phase 2 study investigating the safety and efficacy of MK-1308A, a coformulation of pembrolizumab (PD-1 inhibitor) and quavonlimab (CTLA-4 inhibitor) plus lenvatinib as first-line therapy for patients with advanced HCC.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    [VIRTUAL] B7 immune checkpoint proteins as mediators of resistance to targeted therapy in renal cancer cells () -  May 30, 2021 - Abstract #EACR2021EACR_1651;    
    Material and Methods In this study, we have analyzed the global expression of B7-family members (including PD-L1, PD-L2, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7) in renal cancer cells upon treatment with clinically relevant targeted therapies, including VEGF inhibitors (Axitinib, Cabozantinib, and Lenvatinib) and mTOR inhibitors (Everolimus and Temsirolimus)...Cell functional assays revealed the potential of specific B7 proteins to mediate intrinsic resistance to targeted therapy in renal cancer cells. Conclusion Our findings highlight novel B7 proteins as actionable immune checkpoint proteins in advanced and metastatic renal cancer cases resistant to current treatments.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    [VIRTUAL] B7 immune checkpoint proteins as mediators of resistance to targeted therapy in renal cancer cells () -  May 30, 2021 - Abstract #EACR2021EACR_1650;    
    Material and Methods In this study, we have analyzed the global expression of B7-family members (including PD-L1, PD-L2, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7) in renal cancer cells upon treatment with clinically relevant targeted therapies, including VEGF inhibitors (Axitinib, Cabozantinib, and Lenvatinib) and mTOR inhibitors (Everolimus and Temsirolimus)...Cell functional assays revealed the potential of specific B7 proteins to mediate intrinsic resistance to targeted therapy in renal cancer cells. Conclusion Our findings highlight novel B7 proteins as actionable immune checkpoint proteins in advanced and metastatic renal cancer cases resistant to current treatments.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    [VIRTUAL] B7 immune checkpoint proteins as mediators of resistance to targeted therapy in renal cancer cells () -  May 30, 2021 - Abstract #EACR2021EACR_1649;    
    Material and Methods In this study, we have analyzed the global expression of B7-family members (including PD-L1, PD-L2, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7) in renal cancer cells upon treatment with clinically relevant targeted therapies, including VEGF inhibitors (Axitinib, Cabozantinib, and Lenvatinib) and mTOR inhibitors (Everolimus and Temsirolimus)...Cell functional assays revealed the potential of specific B7 proteins to mediate intrinsic resistance to targeted therapy in renal cancer cells. Conclusion Our findings highlight novel B7 proteins as actionable immune checkpoint proteins in advanced and metastatic renal cancer cases resistant to current treatments.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    [VIRTUAL] B7 immune checkpoint proteins as mediators of resistance to targeted therapy in renal cancer cells () -  May 30, 2021 - Abstract #EACR2021EACR_1648;    
    Material and Methods In this study, we have analyzed the global expression of B7-family members (including PD-L1, PD-L2, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7) in renal cancer cells upon treatment with clinically relevant targeted therapies, including VEGF inhibitors (Axitinib, Cabozantinib, and Lenvatinib) and mTOR inhibitors (Everolimus and Temsirolimus)...Cell functional assays revealed the potential of specific B7 proteins to mediate intrinsic resistance to targeted therapy in renal cancer cells. Conclusion Our findings highlight novel B7 proteins as actionable immune checkpoint proteins in advanced and metastatic renal cancer cases resistant to current treatments.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date, Metastases:  Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  May 28, 2021   
    P1,  N=15, Recruiting, 
    Conclusion Our findings highlight novel B7 proteins as actionable immune checkpoint proteins in advanced and metastatic renal cancer cases resistant to current treatments. Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma (clinicaltrials.gov) -  May 26, 2021   
    P1b,  N=30, Active, not recruiting, 
    This allows us to rapidly link in vitro and in vivo efficacy both identifying and testing novel therapies in immunocompetent mice with the ultimate aim of guiding precision medicine trials in human HCC patients. Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
  • ||||||||||  lenvatinib / Generic mfg.
    Journal, Adverse events:  Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer. (Pubmed Central) -  May 25, 2021   
    Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022 Prophylaxis, regular monitoring and symptomatic management with appropriate short treatment breaks and, for persistent adverse events, dose reductions, are recommended to enable patients to remain on the optimal dose regimen.
  • ||||||||||  Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal, PD(L)-1 Biomarker, IO biomarker:  Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. (Pubmed Central) -  May 21, 2021   
    Since May 2020, the atezolizumab plus bevacizumab combination (immunotherapy plus anti-VEGF) has become the new reference standard in first-line HCC treatment...Phase III clinical trials have recently suggested the efficacy of novel anti-angiogenic factors such as cabozantinib and ramucirumab as a second-line treatment option...This paper aims to perform a systematic review describing the evolving treatment options for HCC over the last decades, ranging from neoadjuvant treatment to systemic therapy of advanced-stage HCC. With the landscape of HCC treatment shifting towards novel agents the forming of a new therapeutic algorithm for HCC seems to be imperative.